An interventional study of Amoxicillin/CA and IV ceftriaxone in Community-acquired Pneumonia, sponsored by RESnTEC, Institute of Research. Not yet recruiting at 1 site in Pakistan. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2024-08-01.
Sponsored by RESnTEC, Institute of Research · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing amoxicillin in Community-Acquired Pneumonia — 5 open to participants now, 5 under way, 2 of them phase 3. Amoxicillin · Community-Acquired Pneumonia.
Among the 12 studies testing amoxicillin in Community-Acquired Pneumonia, this one is the 8th largest by planned enrollment, is one of 3 that started in 2024, is one of 2 with no phase, and was the 11th registered.
325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.
Browse Community-Acquired Pneumonia studies →5 of the 12 studies testing amoxicillin in Community-Acquired Pneumonia are open now, in 4 countries. Recruiting first, the newest first:
Medical College of Wisconsin · Sites in United States
Ages 3 mo–18 yrs
Nantes University Hospital · Sites in France
Ages 65+
St. Justine's Hospital · Sites in Canada
Ages 3 mo–18 yrs · Healthy volunteers
Khyber Teaching Hospital · Sites in Pakistan
Ages 3 mo–5 yrs
By country, each count listing its studies:
Amoxicillin: first FDA approval 1974 (AMOXIL). What it is approved for, and how studies give it, is on its page →
Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.
This study: 2 Years to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 2 · Phase 4 5
First in 2005; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 114 is below the median of 246 across 196 interventional studies indexed under Community-Acquired Pneumonia.
Median enrollment 243 across the 12 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 10 most frequent:
RESnTEC, Institute of Research is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
RESnTEC, Institute of Research has 1 study filed under Community-Acquired Pneumonia — fewer than ten, so there is no comparison to draw.
3 of the studies testing amoxicillin in Community-Acquired Pneumonia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06229288Phase 3Nantes University HospitalAmoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward | 2027-05-25 |
| NCT03031210Phase 3St. Justine's HospitalTwice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia. | 2027-06-01 |
| NCT07647835Khyber Teaching Hospital3 vs. 5 Days of Amoxicillin for Childhood Pneumonia: An RCT | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies testing amoxicillin in Community-Acquired Pneumonia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The efficacy of oral amoxicillin is considered equal to that of ceftriaxone in community-acquired pneumonia among children. Also, there are some factors that contradict the usage of ceftriaxone, like antibiotic resistance, adverse reactions, drug cost, and the and the chances of IV trauma and infection, which is a major problem in developing countries. Therefore, this study was planned to determine the efficacy of oral amoxicillin compared with intravenous (IV) ceftriaxone in the treatment of uncomplicated ceftriaxone in community acquired pneumonia in children less than 5 years of age.
The efficacy of oral amoxicillin is considered equal to that of ceftriaxone in community-acquired pneumonia among children. Also, there are some factors that contradict the usage of ceftriaxone, like antibiotic resistance, adverse reactions, drug cost, and the and the chances of IV trauma and infection, which is a major problem in developing countries. Therefore, this study was planned to determine the efficacy of oral amoxicillin compared with intravenous (IV) ceftriaxone in the treatment of uncomplicated ceftriaxone in community acquired pneumonia in children less than 5 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this group will receive IV amoxicillin/CA at a dose of 100 mg per kg per day in 3 divided doses for a maximum period of 7 days.
Drug: Amoxicillin/CA
Patients in this group will receive IV ceftriaxone at a dose of 75 mg per kg per day in 2 divided doses for a maximum period of 7 days.
Drug: IV ceftriaxone
Drug page: AmoxicillinStudies of AmoxicillinAmoxicillin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Patients will receive IV amoxicillin/CA at a dose of 100 mg per kg per day in 3 divided doses for a maximum period of 7 days.
Patients will receive IV ceftriaxone at a dose of 75 mg per kg per day in 2 divided doses for a maximum period of 7 days.
Free from fever
Efficacy will be labeled yes where fever symptoms are resolved (temperature = 98.6ºF) within 3 days.
Time frame: 3 days
Plan to share: No — Data can be shared with other researchers on a reasonable request.
No publications or documents are linked to this record.
Start is estimated for Oct 2024; primary completion for Sep 2025, 11 months later.
Of 42 non-industry interventional studies with no phase under Community-Acquired Pneumonia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 38. This study's planned 11 months is below that.
Counting every sponsor, half of 43 studies reached it within 24 months; a quarter within 14 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Amoxicillin · Ceftriaxone
Community-Acquired Pneumonia →
RESnTEC, Institute of Research